Current Status of Messenger RNA Delivery Systems
Messenger RNA is emerging as a highly versatile biological construct for creation of impactful medicines. mRNA vaccines directed toward infectious disease and cancer are in clinical development with encouraging early reads on tolerability and efficacy. The use of mRNA to direct intense but transient...
Gespeichert in:
| Veröffentlicht in: | Nucleic acid therapeutics 2018-06, Vol.28 (3), p.158-165 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 165 |
|---|---|
| container_issue | 3 |
| container_start_page | 158 |
| container_title | Nucleic acid therapeutics |
| container_volume | 28 |
| creator | Stanton, Matthew G. |
| description | Messenger RNA is emerging as a highly versatile biological construct for creation of impactful medicines. mRNA vaccines directed toward infectious disease and cancer are in clinical development with encouraging early reads on tolerability and efficacy. The use of mRNA to direct intense but transient expression of paracrine factors is finding utility in reprogramming progenitor cells for wound healing and cardiac regeneration and for stimulation of antitumor immune responses, at least preclinically as we await clinical results. The use of mRNA for prolonged and repeated expression of proteins and enzymes to treat rare, typically monogenic disease is nearing clinical entry. These uses of mRNA require delivery solutions, and the application of and improvement to existing nanoparticle nucleic acid delivery systems have jump started the pace of development and reenergized the field of particle based nucleic acid delivery. The current status of mRNA delivery is reviewed in this article with an eye toward clinical tractability. |
| doi_str_mv | 10.1089/nat.2018.0726 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2030912007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2051763400</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-44a10bb4b9f3625630ad5a648a59d61e88ffc7226ca719b22d0abb73a2a38e643</originalsourceid><addsrcrecordid>eNqF0MtLw0AQBvBFFFtqj14l4MVL6uwzm2OpT_ABVs9hN5lISprU3Y3Q_96E1h68uJdZhh8fw0fIOYUZBZ1eNybMGFA9g4SpIzJmVKYx50IeH_48GZGp9yvonwQQWp6SEUuV1pomYwKLzjlsQrQMJnQ-asvoGb3H5hNd9PYyj26wrr7RbaPl1gdc-zNyUpra43Q_J-Tj7vZ98RA_vd4_LuZPcc6VDLEQhoK1wqYlV0wqDqaQRgltZFooilqXZZ4wpnKT0NQyVoCxNuGGGa5RCT4hV7vcjWu_OvQhW1c-x7o2DbadzxhwSCkDSHp6-Yeu2s41_XW9kjRRXAD0Kt6p3LXeOyyzjavWxm0zCtnQZta3mQ1tZkObvb_Yp3Z2jcVB_3bXA74Dw9o0TV2hRRf-if0Bc2d-Yw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2051763400</pqid></control><display><type>article</type><title>Current Status of Messenger RNA Delivery Systems</title><source>Alma/SFX Local Collection</source><creator>Stanton, Matthew G.</creator><creatorcontrib>Stanton, Matthew G.</creatorcontrib><description>Messenger RNA is emerging as a highly versatile biological construct for creation of impactful medicines. mRNA vaccines directed toward infectious disease and cancer are in clinical development with encouraging early reads on tolerability and efficacy. The use of mRNA to direct intense but transient expression of paracrine factors is finding utility in reprogramming progenitor cells for wound healing and cardiac regeneration and for stimulation of antitumor immune responses, at least preclinically as we await clinical results. The use of mRNA for prolonged and repeated expression of proteins and enzymes to treat rare, typically monogenic disease is nearing clinical entry. These uses of mRNA require delivery solutions, and the application of and improvement to existing nanoparticle nucleic acid delivery systems have jump started the pace of development and reenergized the field of particle based nucleic acid delivery. The current status of mRNA delivery is reviewed in this article with an eye toward clinical tractability.</description><identifier>ISSN: 2159-3337</identifier><identifier>EISSN: 2159-3345</identifier><identifier>DOI: 10.1089/nat.2018.0726</identifier><identifier>PMID: 29688817</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Antigens ; Antitumor activity ; Cancer ; Cells (biology) ; Gene expression ; Heart diseases ; Immune response ; Infectious diseases ; Lipids ; mRNA ; mRNA vaccines ; Nanoparticles ; Nucleic acids ; Paracrine signalling ; Progenitor cells ; Proteins ; Rabies ; Regeneration ; Reviews ; Ribonucleic acid ; RNA ; Stem cells ; Vaccines ; Wound healing</subject><ispartof>Nucleic acid therapeutics, 2018-06, Vol.28 (3), p.158-165</ispartof><rights>2018, Mary Ann Liebert, Inc.</rights><rights>(©) Copyright 2018, Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-44a10bb4b9f3625630ad5a648a59d61e88ffc7226ca719b22d0abb73a2a38e643</citedby><cites>FETCH-LOGICAL-c365t-44a10bb4b9f3625630ad5a648a59d61e88ffc7226ca719b22d0abb73a2a38e643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29688817$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stanton, Matthew G.</creatorcontrib><title>Current Status of Messenger RNA Delivery Systems</title><title>Nucleic acid therapeutics</title><addtitle>Nucleic Acid Ther</addtitle><description>Messenger RNA is emerging as a highly versatile biological construct for creation of impactful medicines. mRNA vaccines directed toward infectious disease and cancer are in clinical development with encouraging early reads on tolerability and efficacy. The use of mRNA to direct intense but transient expression of paracrine factors is finding utility in reprogramming progenitor cells for wound healing and cardiac regeneration and for stimulation of antitumor immune responses, at least preclinically as we await clinical results. The use of mRNA for prolonged and repeated expression of proteins and enzymes to treat rare, typically monogenic disease is nearing clinical entry. These uses of mRNA require delivery solutions, and the application of and improvement to existing nanoparticle nucleic acid delivery systems have jump started the pace of development and reenergized the field of particle based nucleic acid delivery. The current status of mRNA delivery is reviewed in this article with an eye toward clinical tractability.</description><subject>Antigens</subject><subject>Antitumor activity</subject><subject>Cancer</subject><subject>Cells (biology)</subject><subject>Gene expression</subject><subject>Heart diseases</subject><subject>Immune response</subject><subject>Infectious diseases</subject><subject>Lipids</subject><subject>mRNA</subject><subject>mRNA vaccines</subject><subject>Nanoparticles</subject><subject>Nucleic acids</subject><subject>Paracrine signalling</subject><subject>Progenitor cells</subject><subject>Proteins</subject><subject>Rabies</subject><subject>Regeneration</subject><subject>Reviews</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>Stem cells</subject><subject>Vaccines</subject><subject>Wound healing</subject><issn>2159-3337</issn><issn>2159-3345</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqF0MtLw0AQBvBFFFtqj14l4MVL6uwzm2OpT_ABVs9hN5lISprU3Y3Q_96E1h68uJdZhh8fw0fIOYUZBZ1eNybMGFA9g4SpIzJmVKYx50IeH_48GZGp9yvonwQQWp6SEUuV1pomYwKLzjlsQrQMJnQ-asvoGb3H5hNd9PYyj26wrr7RbaPl1gdc-zNyUpra43Q_J-Tj7vZ98RA_vd4_LuZPcc6VDLEQhoK1wqYlV0wqDqaQRgltZFooilqXZZ4wpnKT0NQyVoCxNuGGGa5RCT4hV7vcjWu_OvQhW1c-x7o2DbadzxhwSCkDSHp6-Yeu2s41_XW9kjRRXAD0Kt6p3LXeOyyzjavWxm0zCtnQZta3mQ1tZkObvb_Yp3Z2jcVB_3bXA74Dw9o0TV2hRRf-if0Bc2d-Yw</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Stanton, Matthew G.</creator><general>Mary Ann Liebert, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20180601</creationdate><title>Current Status of Messenger RNA Delivery Systems</title><author>Stanton, Matthew G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-44a10bb4b9f3625630ad5a648a59d61e88ffc7226ca719b22d0abb73a2a38e643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antigens</topic><topic>Antitumor activity</topic><topic>Cancer</topic><topic>Cells (biology)</topic><topic>Gene expression</topic><topic>Heart diseases</topic><topic>Immune response</topic><topic>Infectious diseases</topic><topic>Lipids</topic><topic>mRNA</topic><topic>mRNA vaccines</topic><topic>Nanoparticles</topic><topic>Nucleic acids</topic><topic>Paracrine signalling</topic><topic>Progenitor cells</topic><topic>Proteins</topic><topic>Rabies</topic><topic>Regeneration</topic><topic>Reviews</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>Stem cells</topic><topic>Vaccines</topic><topic>Wound healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stanton, Matthew G.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database (ProQuest)</collection><collection>ProQuest Biological Science Journals</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nucleic acid therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stanton, Matthew G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current Status of Messenger RNA Delivery Systems</atitle><jtitle>Nucleic acid therapeutics</jtitle><addtitle>Nucleic Acid Ther</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>28</volume><issue>3</issue><spage>158</spage><epage>165</epage><pages>158-165</pages><issn>2159-3337</issn><eissn>2159-3345</eissn><abstract>Messenger RNA is emerging as a highly versatile biological construct for creation of impactful medicines. mRNA vaccines directed toward infectious disease and cancer are in clinical development with encouraging early reads on tolerability and efficacy. The use of mRNA to direct intense but transient expression of paracrine factors is finding utility in reprogramming progenitor cells for wound healing and cardiac regeneration and for stimulation of antitumor immune responses, at least preclinically as we await clinical results. The use of mRNA for prolonged and repeated expression of proteins and enzymes to treat rare, typically monogenic disease is nearing clinical entry. These uses of mRNA require delivery solutions, and the application of and improvement to existing nanoparticle nucleic acid delivery systems have jump started the pace of development and reenergized the field of particle based nucleic acid delivery. The current status of mRNA delivery is reviewed in this article with an eye toward clinical tractability.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>29688817</pmid><doi>10.1089/nat.2018.0726</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2159-3337 |
| ispartof | Nucleic acid therapeutics, 2018-06, Vol.28 (3), p.158-165 |
| issn | 2159-3337 2159-3345 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2030912007 |
| source | Alma/SFX Local Collection |
| subjects | Antigens Antitumor activity Cancer Cells (biology) Gene expression Heart diseases Immune response Infectious diseases Lipids mRNA mRNA vaccines Nanoparticles Nucleic acids Paracrine signalling Progenitor cells Proteins Rabies Regeneration Reviews Ribonucleic acid RNA Stem cells Vaccines Wound healing |
| title | Current Status of Messenger RNA Delivery Systems |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T16%3A12%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20Status%20of%20Messenger%20RNA%20Delivery%20Systems&rft.jtitle=Nucleic%20acid%20therapeutics&rft.au=Stanton,%20Matthew%20G.&rft.date=2018-06-01&rft.volume=28&rft.issue=3&rft.spage=158&rft.epage=165&rft.pages=158-165&rft.issn=2159-3337&rft.eissn=2159-3345&rft_id=info:doi/10.1089/nat.2018.0726&rft_dat=%3Cproquest_cross%3E2051763400%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2051763400&rft_id=info:pmid/29688817&rfr_iscdi=true |